Pharmacologic treatment of attention-deficit hyperactivity disorder

被引:9
作者
Donald E. Greydanus
机构
[1] Michigan State University,Pediatrics and Human Development
[2] Kalamazoo Center for Medical Studies Kalamazoo,undefined
关键词
Attention deficit hyperactivity disorder; Methylphenidate; Amphetamines; Atomoxetine; Bupropion;
D O I
10.1007/BF02731672
中图分类号
学科分类号
摘要
Attention-deficit hyperactivity disorder (ADHD) is highly prevalent in children and adolescents. Highly effective pharmacological treatments are available that allow the child and the adolescent to function at his/her full potential. Various preparations of methylphenidate and amphetamines have been used for a long time in the treatment of ADHD. This article reviews these and some of the newer drugs used in the treatment of ADHD, including atomoxetine and bupropion.
引用
收藏
页码:953 / 960
页数:7
相关论文
共 36 条
[11]  
Staufer WB(1991)Therapies for hyperactive children: Comparisons, combinations, and compromises J Consult Clin Psychol 59 126-137
[12]  
Greydanus DE(1937)The behavior of children receiving benzedrine Am J Psychiatry 94 577-585
[13]  
Wolraich ML(2000)ADHD in adolescence J Adolesc Health 127 77-78
[14]  
Wibbelsman CJ(2001)The Texas children’s medication algorithm project: report of the texas consensus conference panel on medication treatment of childhood, attention-deficit/hyperactivity disorder. Part I J Am Acad Child Adolesc Psychiatry 39 908-919
[15]  
Brown TE(2005)ADHD N Engl J Med 352 123-125
[16]  
Stein MT(2003)Attention-deficit/ hyperactivity disorder in adolescent males Adolesc Med 14 663-676
[17]  
Swanson JM(2002)Managing stimulant medication for attention-deficit/hyperactivity disorder: An update Pediatr Rev 23 234-236
[18]  
Whalen CK(2001)Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): Implications and applications for primary care providers J Dev Behav Pediatr 22 60-73
[19]  
Henker B(2000)Sudden death of a child treated with imipramine J Child Adolesc Psychopharmacol 10 321-325
[20]  
Bradley C(2001)Sudden death related to selected tricyclic antidepressants in children: Epidemiology, mechanisms and clinical implications Paediatr Drugs 3 613-627